These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 28880838)

  • 1. Aspirin for Prevention of Cardiovascular Disease.
    Mendy VL; Vargas R; Zhang L
    Prev Chronic Dis; 2017 Sep; 14():E77. PubMed ID: 28880838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do clinicians recommend aspirin to patients for primary prevention of cardiovascular disease?
    Fiscella K; Winters PC; Mendoza M; Noronha GJ; Swanger CM; Bisognano JD; Fortuna RJ
    J Gen Intern Med; 2015 Feb; 30(2):155-60. PubMed ID: 25092016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review and study of aspirin utilization for the primary prevention of cardiovascular events in a psychiatric population.
    Victor K; Skelly M; Mulcahy K; Demler TL; Trigoboff E
    Int Clin Psychopharmacol; 2018 Sep; 33(5):274-281. PubMed ID: 29939889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: Benefit or risk?
    Leggio M; Bendini MG; Caldarone E; Lombardi M; Severi P; D'Emidio S; Stavri DC; Armeni M; Bravi V; Mazza A
    Diabetes Metab; 2018 Jun; 44(3):217-225. PubMed ID: 29257747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The present status of aspirin use for primary prevention among hypertensive outpatients in China].
    Liu J; Zhao D; Liu J; Qi Y; Sun JY; Wang W
    Zhonghua Nei Ke Za Zhi; 2016 Apr; 55(4):267-72. PubMed ID: 27030613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. When is the use of aspirin for CVD prevention in women appropriate?
    Manson JE; Bassuk SS
    Menopause; 2014 Jan; 21(1):103-5. PubMed ID: 23695505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness model of use of genetic testing as an aid in assessing the likely benefit of aspirin therapy for primary prevention of cardiovascular disease.
    Shiffman D; Slawsky K; Fusfeld L; Devlin JJ; Goss TF
    Clin Ther; 2012 Jun; 34(6):1387-94. PubMed ID: 22560621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose of aspirin in the treatment and prevention of cardiovascular disease: current and future directions.
    Hennekens CH; Sechenova O; Hollar D; Serebruany VL
    J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):170-6. PubMed ID: 17056829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose aspirin for primary prevention of cardiovascular disease.
    Bredie SJ; Wollersheim H; Verheugt FW; Thien T
    Semin Vasc Med; 2003 May; 3(2):177-84. PubMed ID: 15199480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential economic impact of increasing low dose aspirin usage on CVD in the US.
    Manson SC; Benedict A; Pan F; Wittrup-Jensen KU; Fendrick AM
    Curr Med Res Opin; 2010 Oct; 26(10):2365-73. PubMed ID: 20738228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Acetylsalicylic acid does not prevent cardiovascular disease. Poor scientific support for therapeutic guidelines according to primary prevention studies].
    Mooe T
    Lakartidningen; 2006 Sep 20-26; 103(38):2732-6. PubMed ID: 17058766
    [No Abstract]   [Full Text] [Related]  

  • 12. [Low-dosage ASA should not be given as primary prevention. The risk is greater than the benefit--also in high risk of cardiovascular disease].
    Håkansson J; Hernborg A
    Lakartidningen; 2010 Feb 3-9; 107(5):260-2. PubMed ID: 20297567
    [No Abstract]   [Full Text] [Related]  

  • 13. Frequency and practice-level variation in inappropriate aspirin use for the primary prevention of cardiovascular disease: insights from the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence registry.
    Hira RS; Kennedy K; Nambi V; Jneid H; Alam M; Basra SS; Ho PM; Deswal A; Ballantyne CM; Petersen LA; Virani SS
    J Am Coll Cardiol; 2015 Jan; 65(2):111-21. PubMed ID: 25593051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of updated recommendations on acetylsalicylic acid use for primary prevention of cardiovascular disease in Canada: a population-based survey.
    Khalili M; Lepeytre F; Guertin JR; Goupil R; Troyanov S; Bouchard J; Madore F
    CMAJ Open; 2020; 8(1):E41-E47. PubMed ID: 31992558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose aspirin in primary prevention revisited.
    Pines A
    Climacteric; 2014 Jun; 17(3):310-1. PubMed ID: 24945033
    [No Abstract]   [Full Text] [Related]  

  • 16. Aspirin for primary prevention of cardiovascular disease: What do the current USPSTF guidelines say?
    Mallick S; Shroff GR; Linzer M
    Cleve Clin J Med; 2023 May; 90(5):287-291. PubMed ID: 37127334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspirin for primary prevention: yes or no?
    Selak V; Elley CR; Wells S; Rodgers A; Sharpe N
    J Prim Health Care; 2010 Jun; 2(2):92-9. PubMed ID: 20690297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The polypill: an emerging treatment alternative for secondary prevention of cardiovascular disease.
    Hedner T; Kjeldsen SE; Narkiewicz K; Oparil S
    Blood Press; 2016 Oct; 25(5):276-9. PubMed ID: 27071504
    [No Abstract]   [Full Text] [Related]  

  • 19. [Antiaggregation: aspirin].
    Eichenberger A; Pontiggia L; Beer JH
    Ther Umsch; 2003 Jan; 60(1):15-8. PubMed ID: 12638472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasing aspirin use among persons at risk for cardiovascular events in Oklahoma.
    Mallonee S; Daniels CG; Mold JW; Cline TL
    J Okla State Med Assoc; 2010 Jul; 103(7):254-60. PubMed ID: 20821923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.